Biocitech Park, Paris (France), November 15th, 2010. Endotis Pharma, the biopharmaceutical
company dedicated to the discovery and development of small-glyco drugs (SGDs) for
applications in thrombosis and hemato-oncology, announced that it has successfully completed
the first study assessing in healthy subjects the neutralization of the anticoagulant EP217609 by
its specific antidote avidin.
EP217609 and avidin were well tolerated in the 36 healthy subjects enrolled in this study. A
single intravenous bolus of EP217609 achieved a stable anticoagulation during 90 minutes, then
the subsequent administration of avidin triggered a rapid, complete, and irreversible
neutralization of the anticoagulant activity of EP217609 without rebound effects.
EP217609 is a first-in-class synthetic, parenteral anticoagulant that can be neutralized by a
specific antidote avidin (EP5001). EP217609 has a dual mechanism of action combining direct
(free and clot-bound) thrombin inhibition and indirect factor Xa inhibition.
Eric Neuhart, MD, Head of Clinical Research and Development at Endotis Pharma, commented:
“This study confirms the data generated in previous studies performed in healthy subject and
animals. EP217609 and avidin have a predictable and reproducible pharmacodynamic and
pharmacokinetic profile with a low inter-subject variability. ”
Eric Neuhart added: EP217609 and avidin will be developed in extracorporeal circulation for
cardiac surgery as a first indication. EP217609 and avidin could represent the first alternative
to replace heparin and its antidote protamine, used for more than 50 years in cardiac surgery
despite their limitations and side effects. The data generated during phase I clinical studies will
allow the optimization of the phase II clinical program that will be initiated in cardiac surgery
patients in the first half of 2011”.
About Endotis Pharma (www.endotis.com)
Endotis Pharma is a biopharmaceutical company dedicated to the discovery and development of small-glyco drugs
for applications in thrombosis, oncology and hematology. Endotis has developed a breakthrough thrombosis
franchise of parenteral and oral drugs in clinical and preclinical development, and a promising oncology and
hematology discovery platform. Endotis has 32 employees based in Paris and Lille, France.
Disclaimer: The development of new drug technologies is difficult, erratic and unpredictable. Endotis Pharma’s
forecasts and future economic performance depend on research that has yet to be performed and on a number of
other factors. The company's future economic performance may differ significantly from that currently forecast
For more information
Press contact: Alize RP
+33 (0)6 64 18 99 59
Endotis Pharma contact:
Head of Business Development and Licensing
+33 (0) 1 48 46 50 52